BioMarin Pharmaceuticals BMRN Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's business segments — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported business segments — total revenues of $766.21M in Q1 2026.
- How has BioMarin Pharmaceuticals's business segments — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's business segments — total revenues increased by 2.8% year-over-year, from $745.15M to $766.21M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — total revenues?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $2.1B to $3.22B.
- What does business segments — total revenues mean?
- The total amount of money generated from sales within the company's main business segment.
- How do you interpret business segments — total revenues?
- An increase indicates successful product adoption and market expansion, while a decrease may signal competitive pressure or loss of market share.
- How does business segments — total revenues compare across companies?
- Comparable to total segment revenue reported by other specialty biopharmaceutical firms.